DigestRedComo funciona
Red
/
Empresas
Ge
No verificado

Genentech

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

62 Comunicados de prensa

Ver todos los comunicados de prensa
18/11/2025
Industria
Ciencia
Medicina - Varios
Biotecnología
Sanidad
Salud
Farmacéutica
Oncología
Genentech’s Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer
Fuente
Genentech
Editor
Business Wire
1.00
0
10/11/2025
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Industria
Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis
Fuente
Genentech
Editor
Business Wire
1.00
0
03/11/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
Eventos
Ferias y Congresos
Industria
Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025
Fuente
Genentech
Editor
Business Wire
1.00
0
03/11/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Industria
Positive Phase III Data for Genentech’s Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
Fuente
Genentech
Editor
Business Wire
1.00
0
28/10/2025
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Positive Phase III Results for Genentech’s Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome
Fuente
Genentech
Editor
Business Wire
1.00
0
20/10/2025
Eventos
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment
Fuente
Genentech
Editor
Business Wire
1.00
0
20/10/2025
Multimedia
Biotecnología
Higiene alimentaria
Salud
Farmacéutica
Sanidad
Industria
FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis
Fuente
Genentech
Editor
Business Wire
1.00
0
18/10/2025
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Eventos
Industria
Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer
Fuente
Genentech
Editor
Business Wire
1.00
0
17/10/2025
Biotecnología
Salud
Farmacéutica
Óptica
Medicina - Varios
Industria
Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
Fuente
Genentech
Editor
Business Wire
1.00
0
16/10/2025
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Farmacéutica
Salud
Industria
Genentech Expands Xofluza® Access and Affordability for Upcoming Flu Season With Direct-to-Patient Launch
Fuente
Genentech
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0